Rocket Pharmaceuticals has voluntarily withdrawn its biologics marketing application for RP-L102, also known as mozafancogene autotemcel, from the U.S. Food and Drug Administration (FDA). This investigational...
Families across Canada are expressing both hope and frustration as two promising drugs aimed at slowing the progression of Alzheimer’s disease remain unavailable in the country....
